Children, caregivers and health workers' perceptions and experiences of the XTEMP-R tool to improve tuberculosis

Dillon T Wademan1, Willdon J Filander1, Mfundo Mlomzale1

  • 1Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

PubMed

Insights

The XTEMP-R tool simplifies preparing pediatric drug-resistant tuberculosis (DR-TB) medications at home, easing caregiver burden. However, taste and side effects remain challenges for children undergoing DR-TB treatment.

Area of Science:

  • Pediatric infectious diseases
  • Pharmaceutical technology
  • Global health

Background:

  • Treating pediatric drug-resistant tuberculosis (DR-TB) is challenging due to limited child-friendly formulations and poor palatability.
  • Extemporaneous preparation of TB medications is a strategy to improve administration but often requires unavailable pharmaceutical services in high-burden settings.

Purpose of the Study:

  • To explore the experiences and perceptions of children, caregivers, and health workers with the XTEMP-R tool for preparing pediatric DR-TB medication suspensions.
  • To assess the usability and impact of the XTEMP-R tool on home-based treatment preparation and administration.

Main Methods:

  • Qualitative study conducted in South Africa involving interviews and focus group discussions with caregivers and health workers.
  • Interviews with caregivers of children who used the XTEMP-R tool for home administration of DR-TB treatment.
  • Deductive thematic analysis of collected qualitative data.

Main Results:

  • Participants found the XTEMP-R tool easy to use, clean, and store, with appealing design features.
  • The tool simplified treatment preparation and administration, reducing burdens for home users.
  • While usability was improved, challenges with medication palatability, nausea, and side effects persisted.

Conclusions:

  • The XTEMP-R tool shows potential for easing pediatric DR-TB treatment preparation and administration.
  • Further design refinement is needed to address medication palatability and side effects.
  • The tool may foster increased treatment responsibility and agency in children, potentially improving adherence.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
534
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
474
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
827
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.4K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
931
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200